Abstract
We report the case of a 49-year-old patient who developed brain, sternal, and spine metastases almost simultaneously after the radical resection of a yp-T4N0M0 pulmonary pleomorphic carcinoma of the right upper lobe following induction chemotherapy. The left occipital brain metastasis was surgically removed and followed by radiation therapy. The sternal and vertebral metastases were treated with radiation therapy. Concurrently, the immune checkpoint inhibitor nivolumab was administered. After 12 cycles of nivolumab, the two bone metastases were well-controlled. However, the brain metastasis recurred and was surgically removed again. We were able to investigate the tumor-infiltrating lymphocytes in brain metastases resected before and after radio-immunotherapy. The results revealed the increased number of CD8- and CD68-positive cells after the combined therapy compared with before the therapy. In addition, the high-level expression of program death-ligand 1 was maintained in the brain metastasis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S et al (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366:925–931
Kim S, Kim MY, Koh J, Go H, Lee DS, Jeon YK, Chung DH (2015) Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: comparison of sarcomatous and carcinomatous area. Eur J Cancer 51:2698–2707
Ito K, Hataji O, Katsuta K, Kobayashi T, Gabazza E, Yatabe Y et al (2016) “Pseudoprogression” of pulmonary pleomorphic carcinoma during nivolumab therapy. J Thorac Oncol 11:e117–e119
Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC et al (2017) Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 18:895–903
Levy A, Massard C, Sonia JC, Deutsch E (2016) Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: single centre subset analysis from a phase 1/2 trial. Eur J Cancer 68:156–162
Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M et al (2016) Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17:976–983
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R et al (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. https://doi.org/10.1056/NEJMoa1709937
Lakin N, Rulach R, Nowicki S, Kurian KM (2017) Current advances in checkpoint inhibitor: lessons from non-central nervous system cancers and potential for glioblastoma. Front Oncol 7:141. https://doi.org/10.3389/fonc.2017.00141
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical statement
This report was approved by ethics committee of our hospital (No. 110617-13).
Conflict of interest
All authors have declared no conflicts of interest.
About this article
Cite this article
Kodama, K., Maniwa, T., Kimura, Y. et al. Concurrent combination of irradiation and immune checkpoint inhibitor for recurrent pleomorphic carcinoma of the lung. Int Canc Conf J 7, 43–47 (2018). https://doi.org/10.1007/s13691-017-0315-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13691-017-0315-9